Alexandria Venture Investments has participated in an NEA-led round that took the total raised by the metabolic disease drug startup to $60m.
US-based metabolic disease drug developer Metacrine has completed a $22m series B round that included Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities.
New Enterprise Associates (NEA) led the round, which included fellow venture capital firms Arch Venture Partners, Polaris Partners and VenBio, and which took Metacrine’s total funding to about $60m, the company said.
The latter three had joined investment advisory firm EcoR1 Capital to invest in Metacrine as…
